Providing actionable data in a few minutes and allowing immediate early treatment of a peritonitis with the goal of keep a patient on PD
Renal replacement therapy (RRT) is required for 5 million patients with chronic kidney therapy (CKT) globally. Most receive hemodialysis (HD), even though peritoneal dialysis (PD) is safer for patients and at least 2.3 times cheaper. A major reason is the absence of a point of care diagnostic to detect PD peritonitis.
Detact is developing a direct, point of care, diagnostic test which is fast, affordable and provides actionable data: the RenoTact©
RenoTact© is allowing immediate early treatment of a peritonitis
Providing actionable data in a few minutes and allowing immediate early treatment of a peritonitis with the goal of keep a patient on PD longer before resorting to the more expensive and less safe HD.
PD is a cost-effective RRT, which performed at home can give the patient high quality of life.
An easy to use and fast point-of-care (preferably at-home) test that enables early detection of a PD peritonitis, which allows for fast treatment, which would allow the safer and cheaper PD te be available to more patients.
A patient can take a small amount of early morning PD fluid and add this to the receptacle containing the proprietary Detact substrate, shake it for a few seconds and place it in the NIR fluorometer with results showing in seconds. In the case of bacterial presence, antibiotic treatment can start immediately.